Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Researchers at Washington University School of Medicine in St. Louis have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy.
Oncotarget published "Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells" which reported that there was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.
Researchers have created a new open-access database of information on drug candidates and how they are metabolized by the body, which could help speed up the repurposing of old drugs as new treatments.
Oncotarget published "Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells" which reported that this study aimed to investigate whether Hepatocellular Cancer (HCC) cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions.
World-first 3D printed esophageal stents developed by the University of South Australia could revolutionize the delivery of chemotherapy drugs to provide more accurate, effective and personalized treatment for patients with esophageal cancer.
With the advent of pharmacogenomics, machine learning research is well underway to predict the patients' drug response that varies by individual from the algorithms derived from previously collected data on drug responses.
Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.
City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options.
Seated around the dinner table, faculty affiliated with Stanford ChEM-H - one of Stanford University's interdisciplinary institutes - spoke one-by-one, pitching ideas for collaborative research.
The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.
Up to now, patients with inoperable anal cancer, a rare disease, have not had a standard-of-care treatment; palliative care has been the routine for them.
Doctors could soon be administering an entire course of treatment for life-threatening conditions with a 3D printed capsule controlled by magnetic fields thanks to advances made by the University of Sussex researchers.
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.
Now, a researcher at the University of Missouri has found that four antiviral drugs, including remdesivir, a drug originally developed to treat Ebola, are effective in inhibiting the replication of the coronavirus causing COVID-19.
Skin diseases affect half of the world's population, but many treatments are not effective, require frequent injections, or cause significant side effects.
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.
Researchers have found a way to help make chemotherapy more effective in treating colon cancer. They identified a new pathway (RICTOR/mTORC2) as a biological target for the disease.
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
High levels of circ E7 by quantitative RT-PCR predicted improved overall survival in ASCC and analysis of The Cancer Genome Atlas sequencing from HPV-positive head and neck cancer and cervical cancer suggested high circ E7 marked improved survival in 875 subjects.
Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.